title: Role of selectins and fibrinolysis in VTE.
abstract: Venous thromboembolism (VTE) accounts for an estimated 900,000 cases of deep venous thrombosis (DVT) and pulmonary embolism (PE) yearly, resulting in approximately 300,000 deaths [1]. For the past 150 years, Virchow's triad has encompassed the elements of venous thrombogenesis, including stasis, changes in the vessel wall, and thrombogenic changes in the blood. However, in the early 1970s, through the work of Gwendylen Stewart, a relationship between thrombosis and inflammation was suggested. In this review, we will address the role of selectins and fibrinolysis in the process of venous thrombogenesis.
authors.affiliation: Department of Surgery, Ann Arbor, MI, USA. thomasww@umich.edu
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Wakefield
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Myers
authors.forename: Peter K
authors.initials: PK
authors.lastname: Henke
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use; D004195:Disease Models, Animal; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000150:complications*; D010960:Plasminogen Activators / Q000097:blood; D012307:Risk Factors; D019087:Selectins / Q000097:blood*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D019087:Selectins; D010960:Plasminogen Activators